Saturday, October 27, 2012

UDAY BALDOTA, VP - INVESTOR RELATIONS, SUN PHARMA

B&E: Still, there is turmoil in the sector at present, especially if we look at the ever-deteriorating condition of many major players...

UB:
Not really! I don’t agree because the sales growth of the top 12 Indian pharma companies averaged above 20% in the year ended recently. Moreover, as far as Sun is concerned, there is no manpower cut on account of issues in the economy. In fact, our recruitment continues apace. Yes, there was one rare instance though at Caraco, our US subsidiary, where we had to reduce headcount, but that was only because it had problems.

B&E: $200 billion to be earned by generic players by 2014 from patent expiries. What’s your game plan in this regard?

UB:
In our view, generic drugs is a significant, growing and profitable opportunity, worldwide. We are working towards getting a meaningful presence in the worldwide generic industry over the longer term...

B&E: And what about the ‘failed’ Taro deal?

UB:
The deal is still on, with some court decisions awaited...


Source : IIPM Editorial, 2012.

For More IIPM Info, Visit below mentioned IIPM articles.

 
IIPM : The B-School with a Human Face